echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > What is the key of micro core bio investment to start the international authorization?

    What is the key of micro core bio investment to start the international authorization?

    • Last Update: 2019-12-26
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    The micro core biology listed on the science and technology innovation board has multiple halos The company has realized the first global patent authorization for Chinese pharmaceutical enterprises After listing, it has been popular in the capital market, with a price earnings ratio of more than 200 times However, the current operating income of the company is not high Where is the micro bio cow? What is the focus of investment in the future? Bovine in technology: multiple heavyweight product reserves I xidaban anti-cancer mechanism is the global first anti-cancer difficulty lies in the recurrence in the field of tumor treatment Many anti-cancer drugs can improve the effective rate of tumor treatment and prolong the survival period, but the generation, metastasis and recurrence of tumor resistance are still difficult to solve More than 90% of cancer patients died of tumor metastasis and recurrence, which was mainly due to tumor immune escape Micro core biology focuses on the field of epigenetics Many scientific researches have found that epigenetics plays an important role in overcoming tumor immune escape and inducing the differentiation of tumor stem cells related to tumor recurrence Epigenetic drugs have become an important hot spot in drug research and development As an epigenetic drug, sidabamide, independently developed by microchip biology, acts as an HDAC inhibitor by inhibiting the biological activity of HDAC, resulting in changes in gene expression of multiple signaling pathways (i.e., epigenetic changes) for tumor development Sidaban realizes China's first global patent authorization Sidabamide of microchip biology is the first subtype selective HDAC inhibitor in the world The company and its researchers have published 19 high-level papers related to sidabamide In 2017, sidabamide was awarded the "most clinically valuable chemical innovative medicine" by Chinese Academy of Medical Sciences, Chinese Academy of traditional Chinese medicine, China Council for the promotion of medicine and people's network, and also obtained the National Intellectual Property Office and the world "China Patent Gold Award" jointly issued by WIPO In October 2006, the company authorized the rights of xidaban in the United States, Japan, the European Union and other countries or regions through the technology licensing mode of "licensing fee + milestone income + revenue sharing", which pioneered the patent licensing of Chinese innovative drugs in Europe and the United States 2、 Xidabamide is suitable for a variety of cancer indications approved for marketing in 2014 - xidabamide developed by peripheral T-cell lymphoma microchip biology has multiple applicable certificates In 2014, xidabamide was approved for marketing in the second phase of clinical treatment for peripheral T-cell lymphoma, becoming the only second-line treatment drug in China In 2017, it entered the medical insurance, and in 2018, about 1071 patients used xidaban tablets According to the number of patients with peripheral T-cell lymphoma and the number of drug users, it is estimated that the current clinical use rate of xidaban tablets is about 7.44% It is estimated that the theoretical market scale of sidabamide in peripheral T-cell lymphoma is 610 million yuan / year In 2018, the sales volume of xidaban was 147.7 million yuan, and there is still room for improvement in the future The new indication of breast cancer was approved in 2019 Breast cancer is the highest incidence rate in China According to data from the network, the total scale of breast cancer in China has exceeded 32 billion yuan in 2016, up 11.67% compared with the same period last year The total scale of hormone receptor positive advanced breast cancer in China in 2016 is about 7 billion 840 million yuan On November 29, 2019, the drug registration of cidabamide in hormone receptor positive advanced breast cancer has been approved, and it will be sold in 2020 There is a large market space in the field of breast cancer The pharmacological mechanism of cidabamide is novel and the effect is obvious, so we keep looking forward to it Indications of ongoing clinical trials - non-small cell lung cancer is the general term for all lung cancer tissue types except for small cell lung cancer Non-small cell lung cancer accounts for about 85% of the total lung cancer patients According to the estimation of the international cancer research agency, the number of new lung cancer cases in 2018 is 2093900, which is the most new cancer type Non-small cell lung cancer is a kind of disease with large-scale drug use, and the indication of the microbubble xidabamide in non-small cell lung cancer has just entered the clinical stage 3 3、 Sigletta sodium has excellent efficacy The number of diabetic patients in the focus diabetes market is very large In 2017, the number of diabetic patients (20-79 years old) in the world reached 425 million China is the country with the largest number of diabetic patients (20-79 years old), reaching 114 million in 2017 The scale of diabetes drug use is very high According to the data of minenet, the scale of drug use in China's diabetes hospitals in 2016 was 39.7 billion yuan, an increase of 8.77% year on year As a new molecular entity of insulin sensitizer of new generation designed, synthesized, screened and developed by the company, ciglitazone sodium developed by microchip bio belongs to PPAR total agonist, and its novel mechanism is a treatment drug for type 2 diabetes, which can not only control blood sugar, but also treat the disorder of lipid metabolism in diabetic patients At present, ciglitazidine sodium has completed phase III clinical trials Although the income volume is small, the level of micro core biotechnology is in the forefront of the world, at present, only one indication of sidaban is listed, and the company's operating income volume is small In the third quarter of 2016, 2017, 2018 and 2019, the operating revenue was 85 million yuan, 111 million yuan, 147.7 million yuan and 128.6 million yuan respectively At present, the company's listed sidabamide application certificate is in the field of peripheral T-cell lymphoma Peripheral T-cell lymphoma is a small market segment, and the market space for breast cancer, non-small cell lung cancer and diabetes will be larger Among them, sidabamide (breast cancer indication) approved in 2019, sidabamide (non-small cell lung cancer) and sigletta sodium (diabetes) are also close Industrialization, the company's income expansion depends on these three products The investment focus is on the company 's heavy-duty products and self-developed micro core biology, cedarbamine, with novel mechanism, is the world' s first drug in this field, and it is the first time that China has granted global patent to the company It belongs to a very promising company However, the company's current operating revenue is not large, and its market value is as high as 22.4 billion yuan, with a P / E ratio of 224 times The current market value already includes the future sales expectation of each product line The market gives a very high valuation to microchip biology Whether the sales revenue of reserve products can be large or not is crucial for the company There are three concerns in the short and medium term: first, in the treatment scheme of peripheral T-cell lymphoma, although the company's scheme is relatively cheap, the cost of 18500 a month is still very expensive for ordinary people In the 2019 health care negotiation, the price of xidaban decreased by 11% year on year, focusing on whether the price reduction can bring about the growth of volume Secondly, in November 2019, xidaban was approved for breast cancer indications, and the sales volume in 2020 needs to be tracked Third, ciglitazidine sodium has completed the third phase of clinical practice, and pays attention to the subsequent drug listing Original author: This article is reprinted by yaozhi.com The copyright belongs to the original author The purpose of reprint is to transmit more information, which does not represent the view of this platform If the content of the work, copyright and other issues are involved, please contact our website message, we will delete the content in the first time.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.